Antifibrinolytic agent could be a treatment for bleeding stroke

Antifibrinolytic agent could be a treatment for bleeding stroke

AI used to instantly and accurately measure blood flow Tranexamic acid is currently used to treat or prevent excessive blood loss from trauma, surgery, tooth removal, nosebleeds and heavy menstruation. For this study, one hundred patients with active brain bleeding were given either intravenous tranexamic acid or placebo within 4.5 hours of symptom onset. Researchers analyzed brain CT scans taken during the 24-hour period after treatment with tranexamic acid or placebo. Researchers found a trend towards reduced hemorrhage expansion in the group treated with tranexamic acid, especially in those treated within 3 hours of the brain bleed. However, this trend was not statistically significant. The finding was consistent with previous research using the medication. Further trials using tranexamic acid are ongoing and focusing on ultra-early treatment - within 2 hours. This is where the greatest opportunity for intervention appears to be. Tranexamic acid is inexpensive, safe and widely available. Our results and others provide great impetus for further, focused research using this treatment." Nawaf Yassi, M.B.B.S., B.Sc., Ph.D., trial investigator and consultant neurologist at the Royal Melbourne Hospital Larger trials focused on patient outcomes are required for this therapy to enter routine clinical practice. Source:



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More